A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
Status:
Completed
Trial end date:
2017-06-13
Target enrollment:
Participant gender:
Summary
This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and
safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile
Idiopathic Arthritis (sJIA). Participants with body weight less than (<) 30 kilograms (kg)
will receive subcutaneous (SC) tocilizumab dose every 2 weeks (Q2W) and participants with
body weight greater than or equal to (>=) 30 kg will receive weekly (QW), for 52 weeks.
Tocilizumab was administered every 10 days until pre-planned interim analysis was performed
and changed to Q2W in participants with body weight <30 kg.